Get the Stockscreener App
57.24
0.47%
0.27
After Hours:
57.30
0.06
+0.10%
Halozyme Therapeutics Inc stock is traded at $57.24, with a volume of 944.91K.
It is up +0.47% in the last 24 hours and down -10.35% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$56.97
Open:
$56.87
24h Volume:
944.91K
Relative Volume:
0.74
Market Cap:
$7.25B
Revenue:
$873.30M
Net Income/Loss:
$337.29M
P/E Ratio:
30.45
EPS:
1.88
Net Cash Flow:
$408.32M
1W Performance:
-2.20%
1M Performance:
-10.35%
6M Performance:
+40.71%
1Y Performance:
+49.84%
1-Day Range:
$56.53
$57.59
1-Week Range:
$55.43
$58.60
52-Week Range:
$32.83
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Trading (HALO) With Integrated Risk Controls - Stock Traders Daily
Chase Investment Counsel Corp Purchases Shares of 91,337 Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Position Lowered by D. E. Shaw & Co. Inc. - MarketBeat
Scientech Research LLC Purchases 11,625 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme CEO Helen Torley sells $1.7 million in stock By Investing.com - Investing.com Australia
Halozyme CEO Helen Torley sells $1.7 million in stock By Investing.com - Investing.com South Africa
Halozyme CEO Helen Torley sells $1.7 million in stock - Investing.com
Halozyme CEO Helen Torley sells $1.7 million in stock By Investing.com - Investing.com UK
Q1 2026 EPS Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO) Boosted by Zacks Research - MarketBeat
Envestnet Asset Management Inc. Raises Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Research Analysts Issue Forecasts for Halozyme Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:HALO) - MarketBeat
Dimensional Fund Advisors LP Has $99.36 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Despite shrinking by US$555m in the past week, Halozyme Therapeutics (NASDAQ:HALO) shareholders are still up 277% over 5 years - Simply Wall St
Profund Advisors LLC Reduces Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Marietta Investment Partners LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme cut to Neutral at J.P. Morgan on valuation - MSN
Renaissance Technologies LLC Has $19.77 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
HOLX Stock Sees Surge of Approximately 2.46% in Last Five Days - Knox Daily
Edgestream Partners L.P. Sells 25,657 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Choreo LLC Makes New $214,000 Investment in Hannon Armstrong Sustainable Infrastructure Capital, Inc. (NYSE:HASI) - Defense World
Long Term Trading Analysis for (HALO) - Stock Traders Daily
Halozyme Therapeutics (NASDAQ:HALO) Downgraded by JPMorgan Chase & Co. - MarketBeat
How analysts predict Halozyme Therapeutics Inc. (HALO) will perform this quarter? - US Post News
E Fund Management Co. Ltd. Sells 2,431 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Mutual of America Capital Management LLC - Defense World
A company insider recently sold 10,000 shares of Halozyme Therapeutics Inc. [HALO]. Should You Sale? - Knox Daily
Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 3.5% After Insider Selling - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Shares Down 3.5% After Insider Selling - Defense World
Halozyme Therapeutics (NASDAQ:HALO) Downgraded by JPMorgan Chase & Co. - Defense World
Halozyme stock cut to Neutral at J.P. Morgan (NASDAQ:HALO) - Seeking Alpha
A better buy-in window may exist right now for Halozyme Therapeutics Inc. (HALO) - SETE News
DekaBank Deutsche Girozentrale Raises Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
State of New Jersey Common Pension Fund D Sells 29,363 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Halozyme downgraded to Neutral from Overweight at JPMorgan - TipRanks
Mutual of America Capital Management LLC Raises Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Five Biotech Stocks Soar: Eyes on Halozyme, United Therapeutics, Harmony, Ligand, and ADMA - geneonline
Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre Sells 10,000 Shares - Defense World
Halozyme Therapeutics executive sells over $1.2m in stock By Investing.com - Investing.com Australia
Halozyme Therapeutics executive sells over $1.2m in stock By Investing.com - Investing.com Canada
Halozyme Therapeutics executive sells over $1.2m in stock - Investing.com
Halozyme Therapeutics executive sells over $1.2m in stock By Investing.com - Investing.com UK
SVP, CHIEF TECHNICAL OFFICER Labarre Michael J. exercised 20,000 shares at a strike of $16.65 and sold $1,249,096 worth of shares (20,000 units at $62.45) (SEC Form 4) - Quantisnow
Hannon Armstrong Sustainable Infrastructure Capital (NYSE:HASI) Reaches New 1-Year High at $35.44 - MarketBeat
Evergreen With Envy: Halozyme’s Subcutaneous Conversions Grow As Rivals Hope To Break In - Pink Sheet
Potential Price Increase for Halozyme Therapeutics Inc. (HALO) After Recent Insider Activity - Knox Daily
Hoth Therapeutics Shares Rally on Positive Alzheimer's Pre-clinical Study Data - MarketWatch
Hoth Therapeutics stock climbs on promising preclinical results for its Alzheimer's drug - MSN
American Century Companies Inc. Has $43 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ - StockTitan
American Century Companies Inc. Has $43 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Hologic (NASDAQ:HOLX) Has More To Do To Multiply In Value Going Forward - Simply Wall St
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):